Could Parkinson’s Gene Therapy Mark a Turning Point for Bayer?

Bayer’s subsidiary AskBio has initiated a European Phase II clinical trial for its innovative gene therapy candidate, AB-1005, targeting Parkinson’s disease. This progression represents a critical milestone for the pharmaceutical conglomerate, potentially signaling a strategic inflection point after a period marked by patent expirations and strategic reviews.

From Safety to Efficacy: A Pivotal Clinical Step

The transition to a Phase II study fundamentally alters the nature of the clinical investigation. The initial Phase I trial focused primarily on establishing the safety and tolerability of AB-1005. Now, the primary objective shifts to demonstrating the therapy’s tangible therapeutic benefit for patients suffering from Parkinson’s disease. Success in this stage is a vital indicator of a drug candidate’s potential, making this a significant validation... Read more...